ReviewStem cell research & therapy2025
The interrelationship between interleukin-17 A and the immunomodulation of mesenchymal stromal cells.
Review in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The interaction between interleukin-17 A (IL-17 A) and mesenchymal stromal cells (MSCs), and its role in immune regulation, is a new research field with broad application potential. This review aims to elucidate the complex relationship between IL-17 A and MSCs in immune regulation, and to provide a theoretical foundation and new insights for the development of immunotherapy strategies based on MSCs in the future. The review begins by summarizing the basic characteristics of IL-17 A and the immunomodulatory function of MSCs, and then delves into the regulation of IL-17 A by MSCs and the impact of IL-17 A on the immunomodulatory effects of MSCs and its potential mechanisms. MSCs can regulate IL-17 A by inhibiting Th17 cell differentiation and modulating the expression of the IL-17 receptor. IL-17 A can influence the immunomodulatory function of MSCs through various means, including enhancing the immunosuppressive effects of MSCs, promoting the migration and homing of MSCs, and stimulating the proliferation and differentiation of MSCs. Consequently, in terms of clinical application prospects, the potential value of the interaction between IL-17 A and MSCs in the treatment of autoimmune diseases, organ transplantation, regenerative medicine, tumor treatment, and other fields offers a novel perspective.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.